Phage therapy: Targeting intestinal bacterial microbiota for the treatment of liver diseases
Year: 2023
Type: review
Abstract: Phage therapy has been overshadowed by antibiotics for decades. However, it is being revisited as a powerful approach against antimicrobial-resistant bacteria. As bacterial microbiota have been mechanistically linked to gastrointestinal and liver diseases, precise editing of the gut microbiota via the selective bactericidal action of phages has prompted renewed interest in phage therapy. In this review, we summarise the basic virological properties of phages and the latest findings on the composition of the intestinal phageome and the changes associated with liver diseases. We also review preclinical and clinical studies assessing phage therapy for the treatment of gastrointestinal and liver diseases, as well as future prospects and challenges.
Source: JHEP Reports
Authors: Jumpei Fujiki, Bernd Schnabl
Language: English
Subfield: Virology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,900
Funders: U.S. Department of Veterans Affairs, Biomedical Laboratory Research and Development, VA Office of Research and Development, Rakuno Gakuen University, National Institutes of Health, Harrington Discovery Institute, University Hospitals, National Institute on Alcohol Abuse and Alcoholism, National Institute of Diabetes and Digestive and Kidney Diseases
Awards: G1523427655, Microbiome as therapeutic target in alcoholic hepatitis, G5258764002, San Diego Digestive Diseases Research Center, The Role of the Intestinal Mycobiome in Alcoholic Liver Disease, Southern California Research Center for ALPD and Cirrhosis, Microbiome and Intestinal Innate Immune Response in Alcoholic Liver Disease
OpenAlex ID: W4386986288